{
  "trial_id": "NCT02630030",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, ECOG performance status, Karnofsky performance status, absolute neutrophil count (ANC), platelet count, hemoglobin level, total bilirubin level, alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, creatinine level, calculated creatinine clearance, prior diagnosis of glioblastoma, prior treatments (chemotherapy, radiotherapy), time since last major surgery, infection status, cardiovascular conditions, use of systemic treatments or inhibitors, hepatitis B or C virus infection status, HIV status, gastrointestinal disease or procedure history, history of other malignancies, peripheral neuropathy grade, participation in other clinical trials, prior treatment with ixazomib.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "Karnofsky performance status",
        "absolute neutrophil count (ANC)",
        "platelet count",
        "hemoglobin level",
        "total bilirubin level",
        "alanine aminotransferase (ALT) level",
        "aspartate aminotransferase (AST) level",
        "creatinine level",
        "calculated creatinine clearance",
        "prior diagnosis of glioblastoma",
        "prior treatments (chemotherapy, radiotherapy)",
        "time since last major surgery",
        "infection status",
        "cardiovascular conditions",
        "use of systemic treatments or inhibitors",
        "hepatitis B or C virus infection status",
        "HIV status",
        "gastrointestinal disease or procedure history",
        "history of other malignancies",
        "peripheral neuropathy grade",
        "participation in other clinical trials",
        "prior treatment with ixazomib"
      ]
    },
    "processed-gen-response": "Age, sex, ECOG performance status, Karnofsky performance status, absolute neutrophil count (ANC), platelet count, hemoglobin level, total bilirubin level, alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, creatinine level, calculated creatinine clearance, prior diagnosis of glioblastoma, prior treatments (chemotherapy, radiotherapy), time since last major surgery, infection status, cardiovascular conditions, use of systemic treatments or inhibitors, hepatitis B or C virus infection status, HIV status, gastrointestinal disease or procedure history, history of other malignancies, peripheral neuropathy grade, participation in other clinical trials, prior treatment with ixazomib."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Absolute Neutrophil Count (ANC), Platelet Count, Hemoglobin, Total Bilirubin, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Calculated Creatinine Clearance, Previous Glioblastoma Diagnosis,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "ECOG Performance Status",
        "Absolute Neutrophil Count (ANC)",
        "Platelet Count",
        "Hemoglobin",
        "Total Bilirubin",
        "Alanine Aminotransferase (ALT)",
        "Aspartate Aminotransferase (AST)",
        "Creatinine",
        "Calculated Creatinine Clearance",
        "Previous Glioblastoma Diagnosis"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Absolute Neutrophil Count (ANC), Platelet Count, Hemoglobin, Total Bilirubin, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine, Calculated Creatinine Clearance, Previous Glioblastoma Diagnosis"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Karnofsky Performance Status, Absolute Neutrophil Count, Platelet Count, Hemoglobin, Total Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Creatinine, Calculated Creatinine Clearance, Eastern Cooperative Oncology Group Performance Status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "ECOG Performance Status",
        "Karnofsky Performance Status",
        "Absolute Neutrophil Count",
        "Platelet Count",
        "Hemoglobin",
        "Total Bilirubin",
        "Alanine Aminotransferase",
        "Aspartate Aminotransferase",
        "Creatinine",
        "Calculated Creatinine Clearance",
        "Eastern Cooperative Oncology Group Performance Status."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Karnofsky Performance Status, Absolute Neutrophil Count, Platelet Count, Hemoglobin, Total Bilirubin, Alanine Aminotransferase, Aspartate Aminotransferase, Creatinine, Calculated Creatinine Clearance, Eastern Cooperative Oncology Group Performance Status."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, Karnofsky performance status, absolute neutrophil count, platelet count, hemoglobin, total bilirubin, ALT, AST, creatinine, calculated creatinine clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "ECOG performance status",
        "Karnofsky performance status",
        "absolute neutrophil count",
        "platelet count",
        "hemoglobin",
        "total bilirubin",
        "ALT",
        "AST",
        "creatinine",
        "calculated creatinine clearance."
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, ECOG performance status, Karnofsky performance status, absolute neutrophil count, platelet count, hemoglobin, total bilirubin, ALT, AST, creatinine, calculated creatinine clearance."
  }
}